[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SRRM4

Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF15230 Serine/arginine repetitive matrix protein C-terminus
Function

Splicing factor specifically required for neural cell differentiation. Acts in conjunction with nPTB/PTBP2 by binding directly to its regulated target transcripts and promotes neural-specific exon inclusion in many genes that function in neural cell differentiation. Required to promote the inclusion of neural-specific exon 10 in nPTB/PTBP2, leading to increased expression of neural-specific nPTB/PTBP2. Also promotes the inclusion of exon 16 in DAAM1 in neuron extracts (By similarity).

> Gene Ontology
 
Biological Process GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000380 alternative mRNA splicing, via spliceosome
GO:0000381 regulation of alternative mRNA splicing, via spliceosome
GO:0000398 mRNA splicing, via spliceosome
GO:0006397 mRNA processing
GO:0007605 sensory perception of sound
GO:0008380 RNA splicing
GO:0043484 regulation of RNA splicing
GO:0048024 regulation of mRNA splicing, via spliceosome
GO:0050684 regulation of mRNA processing
GO:0050954 sensory perception of mechanical stimulus
GO:1903311 regulation of mRNA metabolic process
Molecular Function GO:0003729 mRNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SRRM4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SRRM4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SRRM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0330.951
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5040.725
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7190.656
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1270.768
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1270.844
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5940.00123
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SRRM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRRM4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRRM4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRRM4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRRM4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SRRM4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SRRM4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSRRM4
Nameserine/arginine repetitive matrix 4
Aliases nSR100; neural-specific SR-related protein of 100 kDa; KIAA1853; MU-MB-2.76; medulloblastoma antigen MU-MB-2 ......
Chromosomal Location12q24.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SRRM4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.